Sarepta CEO Doug Ingram buys $2M batch of his biotech’s stock; Express Scripts exploring exclusive gene therapy deals

Sarepta’s shares $SRPT have climbed fast since Doug Ingram stepped in as CEO and had a chance to do some deals and reap the benefits of a promising early-stage gene therapy program. As we’ve noted before, Ingram has a rich pay package tied to the performance of the company’s stock. And he’s demonstrating some personal confidence by adding $2 million worth of shares in the biotech to his portfolio. The stock purchase was outlined in an SEC filing, which has had some prominent distribution this morning on Twitter.

→ After a Phase II failure forced Summit Therapeutics to scrap its Duchenne muscular dystrophy and decimated its stock $SMMT, Summit is hunkering down on its treatment for C. difficile infection. The Oxford-based biotech, which now calls itself “a leader in antibiotic innovation,” announced that it’s received $12 million from BARDA as the first option award in a deal that could give them a total of $62 million. This award, following the $32 million base payment, will fund a Phase III program for ridinilazole expected to begin early 2019.

Express Scripts has reportedly been setting up a new business aimed at distributing pricey gene therapies. They’re looking for exclusive relationships with Spark, BioMarin and bluebird bio, which have all been focused on new development programs.

RXi Pharmaceuticals $RXII has forged a research collaboration with the Karolinska Institutet, exploring their sd-rxRNA compounds against targets involved in T cell and NK cell differentiation as well as the immune cell tumor-induced stress response.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->